ASRT RSI Chart
Last 7 days
12.5%
Last 30 days
38.5%
Last 90 days
27.1%
Trailing 12 Months
-84.7%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 142.1M | 0 | 0 | 0 |
2023 | 162.2M | 168.0M | 169.4M | 152.1M |
2022 | 120.7M | 130.5M | 139.2M | 156.2M |
2021 | 112.2M | 117.0M | 107.9M | 111.0M |
2020 | 198.7M | 167.9M | 137.1M | 106.3M |
2019 | 0 | 0 | 0 | 229.5M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 14, 2024 | tyree james l | sold | -11,462 | 1.1182 | -10,251 | - |
Feb 21, 2024 | patel ajay | acquired | - | - | 17,151 | svp and cfo |
Feb 21, 2024 | schwichtenberg paul | sold (taxes) | -6,719 | 0.79 | -8,506 | svp, cco |
Feb 21, 2024 | schlessinger sam | sold (taxes) | -6,719 | 0.79 | -8,506 | svp, general counsel |
Feb 21, 2024 | schlessinger sam | acquired | - | - | 17,151 | svp, general counsel |
Feb 21, 2024 | schwichtenberg paul | acquired | - | - | 17,151 | svp, cco |
Feb 21, 2024 | patel ajay | sold (taxes) | -6,719 | 0.79 | -8,506 | svp and cfo |
Feb 11, 2024 | schwichtenberg paul | acquired | - | - | 47,348 | see remarks |
Feb 11, 2024 | schlessinger sam | acquired | - | - | 18,939 | svp, general counsel |
Feb 11, 2024 | patel ajay | acquired | - | - | 47,348 | svp and cfo |
Which funds bought or sold ASRT recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -37.34 | -6,849 | 8,780 | -% |
May 16, 2024 | JANE STREET GROUP, LLC | reduced | -54.3 | -38,471 | 26,705 | -% |
May 16, 2024 | ALETHEA CAPITAL MANAGEMENT, LLC | reduced | -3.99 | -19,939 | 123,220 | 0.10% |
May 15, 2024 | Nantahala Capital Management, LLC | reduced | -39.16 | -7,412,090 | 8,893,510 | 0.51% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | reduced | -59.95 | -136,279 | 76,297 | -% |
May 15, 2024 | Gotham Asset Management, LLC | reduced | -41.55 | -13,382 | 14,733 | -% |
May 15, 2024 | TWO SIGMA ADVISERS, LP | reduced | -7.45 | -222,282 | 1,083,560 | -% |
May 15, 2024 | ARMISTICE CAPITAL, LLC | sold off | -100 | -6,206,000 | - | -% |
May 15, 2024 | Squarepoint Ops LLC | reduced | -24.04 | -27,219 | 58,119 | -% |
May 15, 2024 | Engineers Gate Manager LP | reduced | -64.52 | -35,825 | 16,714 | -% |
Unveiling Assertio Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Assertio Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 372.2B | 85.6B | 9.67 | 4.35 | ||||
MRK | 332.3B | 61.4B | 144.1 | 5.41 | ||||
AMGN | 167.7B | 29.5B | 44.55 | 5.68 | ||||
PFE | 162.3B | 57.8B | 129.52 | 2.81 | ||||
GILD | 84.4B | 27.4B | 174.21 | 3.07 | ||||
TEVA | 18.4B | 16.0B | -37.29 | 1.15 | ||||
MID-CAP | ||||||||
ALKS | 4.1B | 1.7B | 9.41 | 2.37 | ||||
PRGO | 4.1B | 4.6B | -528.11 | 0.89 | ||||
BHC | 2.5B | 9.0B | -5.45 | 0.28 | ||||
AMPH | 2.1B | 676.2M | 13.75 | 3.14 | ||||
SMALL-CAP | ||||||||
TLRY | 1.5B | 743.2M | -4.35 | 2.06 | ||||
TXMD | 25.8M | 1.3M | -3.49 | 19.84 | ||||
ACRX | 18.4M | 89.6M | -1.29 | 0.19 | ||||
AGRX | 2.5M | 21.5M | -0.32 | 0.12 | ||||
ACOR | 633.5K | 115.7M | 0 | 0.01 |
Assertio Therapeutics Inc News
Income Statement (Quarterly) | |||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 |
Revenue | -1.6% | 32,448 | 32,985 | 35,627 | 40,991 | 42,466 | 50,352 | 34,212 | 35,131 | 36,538 | 33,329 | 25,472 | 25,373 | 26,839 | 30,176 | 34,565 | 20,617 | 20,917 | 38,032 | 55,147 | 57,203 |
Costs and Expenses | -43.7% | 36,785 | 65,314 | 263,898 | 28,571 | 37,822 | 39,730 | 27,778 | 24,340 | 24,979 | 25,347 | 19,538 | 37,374 | 19,332 | 63,272 | 41,240 | 46,369 | 37,549 | - | 65,280 | 53,585 |
S&GA Expenses | -22.7% | 18,524 | 23,958 | 21,005 | 16,771 | 16,904 | 13,704 | 11,900 | 10,543 | 10,638 | 11,264 | 9,013 | 24,040 | 8,324 | 21,272 | 27,607 | 28,131 | 27,314 | - | 36,117 | 24,755 |
R&D Expenses | -28.4% | 733 | 1,024 | 1,316 | 503 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA Margin | -7.4% | -1.56* | -1.45* | -1.07* | 0.30* | 0.30* | 0.42* | 0.47* | 0.51* | 0.37* | 0.35* | -0.02* | -0.14* | - | - | - | - | - | - | - | - |
Interest Expenses | -100.0% | - | 4,398 | - | - | 1,122 | -1,163 | - | - | 2,327 | 2,437 | 2,495 | 2,605 | 2,684 | 2,598 | 3,050 | 1,604 | 8,674 | - | 13,872 | 14,842 |
Income Taxes | -99.5% | 132 | 25,459 | 50,700 | 3,860 | -2,110 | -79,975 | 210 | 593 | 713 | 434 | 46.00 | -300 | 548 | -10,995 | 1,050 | -9,472 | 2,048 | - | -1,715 | 1,141 |
Earnings Before Taxes | 86.3% | -4,378 | -31,905 | -228,885 | 12,330 | -5,594 | 8,578 | 4,384 | 8,427 | 9,777 | 5,041 | 3,783 | -14,469 | 5,092 | -35,348 | -9,472 | -43,971 | 43,278 | - | 1,616 | -12,464 |
EBT Margin | -6.5% | -1.78* | -1.67* | -1.26* | 0.12* | 0.10* | 0.20* | 0.20* | 0.21* | 0.03* | 0.00* | -0.38* | -0.46* | - | - | - | - | - | - | - | - |
Net Income | 92.1% | -4,510 | -57,384 | -279,544 | 8,470 | -3,484 | 88,553 | 4,174 | 7,834 | 9,064 | 4,607 | 3,737 | -14,169 | 4,544 | -24,353 | -10,522 | -34,499 | 41,230 | -192,626 | 3,331 | -13,605 |
Net Income Margin | -7.4% | -2.34* | -2.18* | -1.10* | 0.58* | 0.60* | 0.70* | 0.18* | 0.19* | 0.03* | -0.01* | -0.28* | -0.38* | - | - | - | - | - | - | - | - |
Free Cashflow | 32.1% | 7,408 | 5,607 | 2,579 | 18,327 | 22,443 | 26,423 | 10,045 | 14,377 | 27,373 | 4,078 | 4,654 | 964 | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2019Q4 |
Assets | -1.6% | 282 | 286 | 380 | 405 | 414 | 414 | 323 | 322 | 339 | 327 | 299 | 312 | 325 | 303 | 333 | 346 | 527 |
Current Assets | 0.8% | 172 | 171 | 185 | 134 | 138 | 132 | 126 | 117 | 125 | 103 | 113 | 119 | 124 | 94.00 | 104 | 135 | 104 |
Cash Equivalents | 9.9% | 81.00 | 73.00 | 77.00 | 70.00 | 69.00 | 65.00 | 65.00 | 52.00 | 61.00 | 37.00 | 59.00 | 54.00 | 61.00 | 21.00 | 35.00 | 59.00 | 42.00 |
Inventory | 2.4% | 39.00 | 38.00 | 43.00 | 19.00 | 16.00 | 14.00 | 14.00 | 12.00 | 9.00 | 7.00 | 5.00 | 7.00 | 9.00 | 12.00 | 13.00 | 25.00 | 3.00 |
Net PPE | -8.6% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 4.00 | 7.00 | 3.00 |
Goodwill | - | - | - | 20.00 | - | - | - | - | - | - | - | - | - | - | - | 9.00 | 9.00 | - |
Liabilities | -0.6% | 147 | 148 | 187 | 151 | 164 | 188 | 188 | 194 | 227 | 224 | 202 | 220 | 220 | 248 | 257 | 261 | 469 |
Current Liabilities | -1.1% | 92.00 | 93.00 | 114 | 79.00 | 95.00 | 95.00 | 92.00 | 116 | 139 | 135 | 100 | 117 | 109 | 133 | 131 | 134 | 185 |
Long Term Debt | 0.3% | 39.00 | 39.00 | 39.00 | 38.00 | 38.00 | 66.00 | 66.00 | 50.00 | 61.00 | 61.00 | 66.00 | 67.00 | 72.00 | 72.00 | 77.00 | 92.00 | 271 |
LT Debt, Current | - | - | - | - | - | 0.00 | 0.00 | - | - | - | 12.00 | - | - | - | 12.00 | - | - | 80.00 |
LT Debt, Non Current | -100.0% | - | 39.00 | 39.00 | 38.00 | 38.00 | 66.00 | 66.00 | 50.00 | 61.00 | 61.00 | 66.00 | 67.00 | 72.00 | 72.00 | 77.00 | 92.00 | 271 |
Shareholder's Equity | -2.5% | 134 | 138 | 193 | 254 | 251 | 226 | 135 | 128 | 112 | 102 | 97.00 | 92.00 | 105 | 56.00 | 76.00 | 85.00 | 58.00 |
Retained Earnings | -0.7% | -656 | -651 | -594 | -314 | -323 | -319 | -408 | -412 | -420 | -429 | -433 | -437 | -423 | -427 | -403 | -393 | -399 |
Additional Paid-In Capital | 0.1% | 791 | 790 | 787 | 569 | 574 | 545 | 543 | 541 | 532 | 532 | 531 | 530 | 529 | 483 | 480 | 478 | 458 |
Shares Outstanding | 0.5% | 95.00 | 95.00 | 95.00 | 57.00 | 56.00 | 48.00 | 48.00 | 46.00 | 45.00 | 45.00 | 43.00 | 41.00 | - | - | - | - | - |
Float | - | - | - | - | 296 | - | - | - | 140 | - | - | - | 68.00 | - | - | - | 90.00 | - |
Cashflow (Quarterly) | |||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 |
Cashflow From Operations | 31.6% | 7,508 | 5,707 | 2,579 | 18,601 | 22,717 | 26,697 | 10,045 | 14,430 | 27,426 | 4,131 | 4,654 | 964 | -4,226 | -5,982 | -14,431 | -20,096 | -25,063 | - | - | - |
Share Based Compensation | -54.3% | 1,207 | 2,642 | 1,865 | 2,205 | 2,446 | 2,388 | 2,400 | 1,734 | 982 | 949 | 867 | 957 | 772 | 3,886 | 1,511 | 3,593 | 1,934 | - | - | - |
Cashflow From Investing | 100.0% | - | -239 | 4,144 | -703 | -105 | -25,784 | -371 | -16,114 | -404 | -18,525 | - | - | - | - | -1.00 | 63,766 | 449,036 | - | - | - |
Cashflow From Financing | 97.7% | -206 | -8,915 | -10.00 | -16,326 | -18,950 | -798 | 2,888 | -7,441 | -2,443 | -7,522 | -356 | -7,569 | 44,473 | -7,969 | -10,234 | -90,240 | -360,107 | - | - | - |
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenues: | ||
Total revenues | $ 32,448 | $ 42,466 |
Costs and expenses: | ||
Cost of sales | 11,177 | 5,467 |
Research and development expenses | 733 | 0 |
Selling, general and administrative expenses | 18,524 | 16,904 |
Change in fair value of contingent consideration | 0 | 9,167 |
Amortization of intangible assets | 5,631 | 6,284 |
Restructuring charges | 720 | 0 |
Total costs and expenses | 36,785 | 37,822 |
(Loss) income from operations | (4,337) | 4,644 |
Other (expense) income: | ||
Debt-related expenses | 0 | (9,918) |
Interest expense | (757) | (1,122) |
Other gain | 716 | 802 |
Total other expense | (41) | (10,238) |
Net loss before income taxes | (4,378) | (5,594) |
Income tax (expense) benefit | (132) | 2,110 |
Net loss and comprehensive loss | $ (4,510) | $ (3,484) |
Basic net loss per share (in dollars per share) | $ (0.05) | $ (0.07) |
Diluted net loss per share (in dollars per share) | $ (0.05) | $ (0.07) |
Shares used in computing basic net loss per share (in shares) | 94,980 | 51,005 |
Shares used in computing diluted net loss per share (in shares) | 94,980 | 51,005 |
Product sales, net | ||
Revenues: | ||
Total revenues | $ 31,862 | $ 41,769 |
Royalties and milestones | ||
Revenues: | ||
Total revenues | $ 586 | $ 697 |
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 80,743 | $ 73,441 |
Accounts receivable, net | 42,610 | 47,663 |
Inventories, net | 38,602 | 37,686 |
Prepaid and other current assets | 10,519 | 12,272 |
Total current assets | 172,474 | 171,062 |
Property and equipment, net | 704 | 770 |
Intangible assets, net | 105,701 | 111,332 |
Other long-term assets | 3,086 | 3,255 |
Total assets | 281,965 | 286,419 |
Current liabilities: | ||
Accounts payable | 15,650 | 13,439 |
Accrued rebates, returns and discounts | 57,870 | 58,137 |
Accrued liabilities | 15,401 | 18,213 |
Contingent consideration, current portion | 2,700 | 2,700 |
Other current liabilities | 823 | 954 |
Total current liabilities | 92,444 | 93,443 |
Long-term debt | 38,621 | 38,514 |
Other long-term liabilities | 16,406 | 16,459 |
Total liabilities | 147,471 | 148,416 |
Commitments and contingencies (Note 15) | ||
Shareholders’ equity: | ||
Common stock, $0.0001 par value, 200,000,000 shares authorized; 95,115,452 and 94,668,523 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively. | 9 | 9 |
Additional paid-in capital | 790,538 | 789,537 |
Accumulated deficit | (656,053) | (651,543) |
Total shareholders’ equity | 134,494 | 138,003 |
Total liabilities and shareholders' equity | $ 281,965 | $ 286,419 |
 | Mr. Daniel A. Peisert |
---|---|
 | assertiotx.com |
 | Pharmaceuticals |
 | 30 |